Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01727869
Show Display Options
Rank Status Study
1 Active, not recruiting Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Condition: Cancer
Interventions: Drug: REGN1400;   Drug: Erlotinib;   Drug: Cetuximab

Indicates status has not been verified in more than two years